Sangamo Therapeutics Announces Research Evaluation And Option Agreement With Prevail, A Wholly Owned Subsidiary Of Lilly, For Novel Engineered Capsids
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics has announced a research evaluation and option agreement with Prevail, a wholly owned subsidiary of Lilly. The agreement is for novel engineered capsids.
July 17, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lilly's subsidiary, Prevail, has entered into a research agreement with Sangamo Therapeutics. This could potentially lead to new developments and growth for Lilly.
The partnership with Sangamo Therapeutics could lead to new developments and growth for Lilly through its subsidiary, Prevail. This could potentially increase Lilly's stock value in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 75
POSITIVE IMPACT
Sangamo Therapeutics has entered into a research agreement with Prevail, a subsidiary of Lilly. This could potentially lead to new developments and growth for the company.
The partnership with Prevail could lead to new developments and growth for Sangamo Therapeutics. This could potentially increase the company's stock value in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100